Arm Holdings plc - American Depositary Shares (ARM)
282.57
-4.11 (-1.43%)
NASDAQ· Last Trade: Aug 8th, 4:04 PM EDT
Druckenmiller only owns one "Magnificent Seven" stock.
Via The Motley Fool · August 8, 2026
Big celebrations demand a massive upgrade in your social life. If you have a huge birthday coming up or a corporate celebration, showing up alone is a terr
Via Talk Markets · August 8, 2026

A five-star hotel by itself doesn't make a trip memorable anymore, not for people who've already stayed there. What tends to stick is something smaller and
Via Talk Markets · August 8, 2026
Organic sales grew 5.8% on volume gains and market share expansion across core brands.
Via The Motley Fool · August 7, 2026
Record financing originations and cost cuts drive adjusted EPS growth.
Via The Motley Fool · August 7, 2026
Record data center royalties and AI chip demand double as Arm accelerates server adoption.
Via The Motley Fool · August 7, 2026
Amazon's net margin expanded to 10.8% while Celsius surged 85.5% in revenue, but profitability tells a different story.
Via The Motley Fool · August 7, 2026
Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa
Via MarketBeat · August 7, 2026
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Chief Executive O
Via MarketBeat · August 7, 2026
Church & Dwight delivered a positive second quarter, with management highlighting broad-based organic sales growth across its divisions and strong consumer d...
Via StockStory · August 7, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via StockStory · August 7, 2026
Today, Aug. 6, 2026, software and cloud names tumbled as investors question valuations while geopolitical tensions added fresh headwinds.
Via The Motley Fool · August 6, 2026
Best PRP P-Shot Clinic in Dubai | Glamorous Clinic in DubaiMen’s wellness is an important part of confidence, comfort, and overall quality of life. With ad
Via Talk Markets · August 6, 2026
Generate Biomedicines focuses on AI-enabled drug discovery.
Via The Motley Fool · August 5, 2026
Palantir, Microsoft, and ServiceNow look like potential big AI SaaS winners.
Via The Motley Fool · August 5, 2026
The company's 2018 decision to stop reporting unit sales in 2019 means investors aren't seeing the full bullish story. Fortunately, IDC is still keeping score.
Via The Motley Fool · August 5, 2026
They're competitors, but they're decreasingly alike. This is going to make a difference sooner or later.
Via The Motley Fool · August 4, 2026
Arm Holdings (ARM) stock surged over 11% on Tuesday after analysts highlighted 100%+ year-over-year data center royalty growth and strong AI chip demand.
Via Benzinga · August 4, 2026
Modern enterprise security teams face endless streams of network alerts every day. Organizations deploy a unified security platform to consolidate critical
Via Talk Markets · August 4, 2026
A broader sell-off in AI stocks weighed on Arm.
Via The Motley Fool · August 3, 2026
Revenue hit $1.31 billion with strong international growth and margin expansion.
Via The Motley Fool · August 3, 2026
Uber and Lyft report earnings this week, but one ride-sharing giant stands out as the much stronger long-term buy.
Via The Motley Fool · August 3, 2026
The consensus bottom-line forecasts most investors were comparing its results to didn't appear to factor in changes stemming from a recent spinoff, or any one-time costs related to it.
Via The Motley Fool · August 3, 2026
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
President and Chief Executive Officer Eran Ophir described the
Via MarketBeat · August 3, 2026
The company is now more confident in hitting its near-term CPU target.
Via The Motley Fool · August 2, 2026